Source: Annual Congress 2010 - New treatments for asthma and COPD
Disease area: Airway diseases, Paediatric lung diseases

Abstract

Background: The onset of asthma may be related to Th2 cytokine dominance at the time when food allergies occur several months after birth.
Objective: This study investigated the effectiveness of early intervention with a Th2 cytokine inhibitor (suplatast tosilate) for prevention of asthma in infants with food allergies and atopic dermatitis.
Methods: Suplatast tosilate dry syrup (6 mg/kg daily) or a histamine H1-blocker (ketotifen fumarate dry syrup: 0.06 mg/kg daily) was administered randomly to 53 infants with atopic dermatitis caused by food allergies. The primary endpoints were the incidence of asthma and the time to the onset of wheezing. The peripheral blood Th1/Th2 ratio, total IgE level, and eosinophil count were measured before and after treatment.
Results: After 24 months of treatment, the prevalence of asthma was significantly lower in the suplatast group (20.8%) than in the ketotifen group (65.6%, p<0.01). Additionally, the time from the start of treatment to the initial episode of wheezing in patients who developed asthma was significantly longer in the suplatast group than the ketotifen group (p<0.01). Furthermore, the eosinophil count was significantly decreased by suplatast treatment (p<0.05), and there was a significant difference between the suplatast and ketotifen groups with respect to both the eosinophil count (p<0.01) and the Th1/Th2 ratio (p<0.05).
Conclusions: These results of the present pilot study suggest that suplatast tosilate is useful for the primary prevention of wheezing and asthma in children.

Rating:

Share or cite this content

Citations should be made in the following way:
S. Yoshihara, M. Ono, Y. Yamada, H. Fukuda, T. Abe, O. Arisaka (Shimotsuga-gun, Japan). Early intervention with suplatast tosilate for prophylaxis of pediatric atopic asthma: A pilot study. Eur Respir J 2010; 36: Suppl. 54, 1161

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of omalizumab in patients with concomitant allergic asthma and atopic dermatitis: a pilot study Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study. Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Safety of omalizumab therapy in children with allergic asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Anti-inflammatory asthma therapy adherence in paediatric patients: The PACMAN cohort study Source: Annual Congress 2010 - Management of airway disease Year: 2010 Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015 Decreasing dose protocol for omalizumab treatment in oral corticosteroid allergic asthma patients Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Efficacy and safety of ciclesonide in the treatment of patients with persistent allergic or non-allergic asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Impact of subcutaneous allergoid AIT on patients with allergic rhinitis and/or asthma: A retrospective real-life, long-term cohort analysis Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020 Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016 Dexamethasone or prednisolone for acute asthma exacerbations in children: a meta-analysis Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019 Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 Therapeutic approach in allergic asthma: ASIT oposit to ICS Source: Annual Congress 2010 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2010 Clinical review of long-term pranlukast therapy in adult patients with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 310s Year: 2004 Patients’ perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting Source: International Congress 2017 – Asthma management Year: 2017 Efficacy of the long-term therapy with simbicort in children with bronchial asthma Source: Eur Respir J 2005; 26: Suppl. 49, 395s Year: 2005 Safety and efficacy of omalizumab in children with allergic asthma Source: Annual Congress 2011 - Treating childhood asthma Year: 2011